We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Sues FDA for Changing ANDA Exclusivity Requirements
Teva Sues FDA for Changing ANDA Exclusivity Requirements
In the latest legal twist over generics of Allergan’s blockbuster dry eye treatment, Restasis, Teva is suing the FDA for changing its policy on eligibility for 180-day marketing exclusivity for generics.